SCHEMBL4526442

SCHEMBL4526442

C=CS(=O)(=O)N1CCC(C(=O)NC2C3CC4CC(C3)CC2C4)CC1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.59
HSD17B10 Q99714 1/20 0.59
HSD11B1 P28845 7/20 0.56
NPSR1 Q6W5P4 1/20 0.41
SMYD3 Q9H7B4 1/20 0.40
EPHX2 P34913 4/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPK1 P28482 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.39
NPC1 O15118 1/20 0.37
EPHX1 P07099 1/20 0.37
KMT2A Q03164 1/20 0.37
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14342766 0.82 NPSR1 (0.43) L3MBTL1HSD17B10HSD11B1NPSR1SMYD3
SCHEMBL4516086 0.81 L3MBTL1 (0.65) L3MBTL1HSD17B10HSD11B1NPSR1EPHX2
SCHEMBL4526450 0.77 EPHX2 (0.53) NPSR1EPHX2ALDH1A1LMNAEPHX1
SCHEMBL3930409 0.74 EPHX2 (0.66) L3MBTL1EPHX2ALDH1A1GAANPC1
SCHEMBL3927960 0.72 HSD17B10 (0.65) L3MBTL1HSD17B10HSD11B1EPHX2ALDH1A1
SCHEMBL3928605 0.72 EPHX2 (0.67) EPHX2ALDH1A1KMT2A
SCHEMBL3918138 0.72 HSD11B1 (0.55) L3MBTL1HSD17B10HSD11B1EPHX2ALDH1A1
SCHEMBL3923982 0.71 HSD17B10 (0.63) L3MBTL1HSD17B10HSD11B1EPHX2LMNA
SCHEMBL3927948 0.71 HSD17B10 (0.63) L3MBTL1HSD17B10HSD11B1EPHX2ALDH1A1
SCHEMBL3920458 0.71 HSD11B1 (0.69) L3MBTL1HSD17B10HSD11B1EPHX2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306048-A1 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-12-10 US claimed
US-20090306048-A1 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-12-10 US disclosed
US-20090306048-A1 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-12-10 US disclosed
US-20090306048-A1 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306048-A1 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HSD11B1, HSD3B1, CES1 L3MBTL1 4795/4885HSD17B10 19/4885HSD11B1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.